Quarterly report pursuant to sections 13 or 15(d)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v2.4.0.6
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) (USD $)
3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Jun. 30, 2011
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]          
Proceeds from the inventory sales       $ 504,857  
Loss on the sale of research and development inventory 0 0 0 (1,934,630)  
Total amount of inventory sold at book value       $ 2,439,487  
Potentially dilutive securities 0.7   0.7   1.9
Board Members Chief Scientific Officer, Chief Medical Officer And a Board member [Member]
         
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]          
Options to purchase shares of common stock 119,325        
Employees and Board Members [Member]
         
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]          
Options to purchase shares of common stock     506,559